pioglitazone + metformin + insulin

Pioglitazone + metformin + insulin refers to the combined use of three anti-diabetic agents for the management of type 2 diabetes. Pioglitazone is a thiazolidinedione that improves insulin sensitivity in peripheral tissues and the liver, leading to increased glucose uptake and decreased hepatic glucose output. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and enhances peripheral glucose uptake and utilization. Insulin is an endogenous hormone or exogenous medication that facilitates cellular uptake of glucose from the bloodstream. This combination therapy may be used in patients with type 2 diabetes who require multiple mechanisms to achieve glycemic control when monotherapy or dual therapy are insufficient.